Journal Article

Reply to the letter to the editor ‘Patients' preference and informed consent’ by Pumo et al.

X. Pivot and Z. Machackova

in Annals of Oncology

Published on behalf of European Society for Medical Oncology

Volume 26, issue 6, pages 1269-1270
Published in print June 2015 | ISSN: 0923-7534
Published online March 2015 | e-ISSN: 1569-8041 | DOI: https://dx.doi.org/10.1093/annonc/mdv145
Reply to the letter to the editor ‘Patients' preference and informed consent’ by Pumo et al.

Show Summary Details

Preview

In PrefHer, patient preference for s.c. trastuzumab was overwhelming. Patients were informed of the s.c. and i.v. safety profiles and they themselves reported fewer side effects with s.c. (one of the main reasons for preferring s.c.). Safety data were consistent with previous reports, including HannaH, and confirmed similarity between the s.c. and i.v. formulations.

Journal Article.  717 words. 

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.